IGFBP-4 and PAPP-A in normal physiology and disease
Growth Hormone & IGF Research · 2018-08 · 41 · 7-22
DOI: 10.1016/j.ghir.2018.05.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Growth Hormone & IGF Research, 2018-08. Verfasst von Rikke Hjortebjerg. Beteiligte Einrichtung: Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark; The Danish Diabetes Academy, Ode…. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 207 Literaturangaben. Gefördert von: Novo Nordisk Fonden, Hjerteforeningen, Aarhus Universitet.
Abstract (Originalsprache)
Insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) is a modulator of the IGF system, exerting both inhibitory and stimulatory effects on IGF-induced cellular growth. IGFBP-4 is the principal substrate for the enzyme pregnancy-associated plasma protein-A (PAPP-A). Through IGF-dependent cleavage of IGFBP-4 in the vicinity of the IGF receptor, PAPP-A is able to increase IGF bioavailability and stimulate IGF-mediated growth. Recently, the stanniocalcins (STCs) were identified as novel inhibitors of PAPP-A proteolytic activity, hereby adding additional members to the seemingly endless list of proteins belonging to the IGF family. Our understanding of these proteins has advanced throughout recent years, and there is evidence to suggest that the role of IGFBP-4 and PAPP-A in defining the relationship between total IGF and IGF bioactivity can be linked to a number of pathological conditions. This review provides an overview of the experimental and clinical findings on the IGFBP-4/PAPP-A/STC axis as a regulator of IGF activity and examines the conundrum surrounding extrapolation of circulating concentrations to tissue action of these proteins. The primary focus will be on the biological significance of IGFBP-4 and PAPP-A in normal physiology and in pathophysiology with emphasis on metabolic disorders, cardiovascular diseases, and cancer. Finally, the review assesses current new trajectories of IGFBP-4 and PAPP-A research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Laboratory, Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark; The Danish Diabetes Academy, Odense, Denmark. Electronic address: rikke.hjortebjerg@clin.au.dk.
Förderung
- Novo Nordisk Fonden
- Hjerteforeningen
- Aarhus Universitet
- Danish Diabetes Academy
Zitieren
APA
Hjortebjerg, R. (2018). IGFBP-4 and PAPP-A in normal physiology and disease. Growth Hormone & IGF Research, 41, 7-22. https://doi.org/10.1016/j.ghir.2018.05.002
Vancouver
Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease. Growth Hormone & IGF Research. 2018;41:7-22. doi:10.1016/j.ghir.2018.05.002
BibTeX
@article{Hjortebjerg2018,
author = {Hjortebjerg, Rikke},
title = {IGFBP-4 and PAPP-A in normal physiology and disease},
journal = {Growth Hormone & IGF Research},
year = {2018},
volume = {41},
pages = {7--22},
doi = {10.1016/j.ghir.2018.05.002}
}
EUVIMED